Denise L Q Prado, Thaissa M Faria, Adeylson G Ribeiro, Luiz Fernando Lopes
{"title":"Disparities in the time and pilgrimage of families of children with cancer until arrival at a reference center for treatment in Brazil.","authors":"Denise L Q Prado, Thaissa M Faria, Adeylson G Ribeiro, Luiz Fernando Lopes","doi":"10.1080/08880018.2025.2543588","DOIUrl":null,"url":null,"abstract":"<p><p>This study assessed the timeline from the initial presentation of symptoms of major cancers to the arrival at and diagnosis by the reference center for pediatric oncology in Barretos, São Paulo, Brazil. The goal was to examine the flow of care within the healthcare system and identify disparities indicative of inequitable access to health services. We conducted a cross-sectional analysis of patient data over eight years. Quantitative variables were examined using median values, T-tests, Kruskal-Wallis tests, ANOVA, Bonferroni adjustments, and pairwise comparisons. Categorical variables were analyzed using the Chi-square test, with a significance threshold set at 5%. A total of 508 patients with malignant cancers were studied. Patients with hematologic cancers experienced the shortest median times from initial symptom perception (2 days), to the first healthcare visit (1 day), onward referral to a specialized center (30 days), and final diagnosis (35 days). This is in contrast to patients with central nervous system cancers (2, 3, 90, and 112.5 days respectively) and bone cancers (20, 7, 60, and 90 days respectively). Families from municipalities ranked lower on the GeoSES socioeconomic scale reported longer durations before recognizing initial symptoms (p-value = 0.037). Low initial diagnostic suspicion and systemic delays are primary obstacles that need addressing to enhance the diagnosis and treatment of pediatric cancer in Brazil's most populous state.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"333-343"},"PeriodicalIF":1.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2543588","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study assessed the timeline from the initial presentation of symptoms of major cancers to the arrival at and diagnosis by the reference center for pediatric oncology in Barretos, São Paulo, Brazil. The goal was to examine the flow of care within the healthcare system and identify disparities indicative of inequitable access to health services. We conducted a cross-sectional analysis of patient data over eight years. Quantitative variables were examined using median values, T-tests, Kruskal-Wallis tests, ANOVA, Bonferroni adjustments, and pairwise comparisons. Categorical variables were analyzed using the Chi-square test, with a significance threshold set at 5%. A total of 508 patients with malignant cancers were studied. Patients with hematologic cancers experienced the shortest median times from initial symptom perception (2 days), to the first healthcare visit (1 day), onward referral to a specialized center (30 days), and final diagnosis (35 days). This is in contrast to patients with central nervous system cancers (2, 3, 90, and 112.5 days respectively) and bone cancers (20, 7, 60, and 90 days respectively). Families from municipalities ranked lower on the GeoSES socioeconomic scale reported longer durations before recognizing initial symptoms (p-value = 0.037). Low initial diagnostic suspicion and systemic delays are primary obstacles that need addressing to enhance the diagnosis and treatment of pediatric cancer in Brazil's most populous state.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.